caspofungin

(redirected from Cancidas)
Also found in: Wikipedia.

caspofungin

 [kas″po-fun´jin]
an antifungal used as the acetate salt in the treatment of invasive aspergillosis, administered intravenously.

caspofungin

(kas'pō-fŭn-jin),
A member of the echinocandin class of antifungal compounds targeting the fungal cell wall.

caspofungin

/cas·po·fun·gin/ (kas″po-fun´jin) an antifungal used as the acetate salt in the treatment of invasive aspergillosis.

caspofungin

a beta-glucan synthase inhibitor used as a broad spectrum antifungal agent.
References in periodicals archive ?
s (NYSE: MRK-Free Report) Cancidas (intravenous) followed by Vfend (oral) for the treatment of candidemia and other invasive candida infections.
Cancidas was approved in January 2001 as a treatment for fungal infections.
Decision Resources (Waltham, MA), one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, said that, because of their improvements in safety and efficacy, physicians are increasingly prescribing next-generation antifungals such as Pfizer's Vfend, Schering-Plough's Noxafil, Merck's Cancidas, Astellas' Mycamine and Pfizer's Eraxis.
In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance [abstract 196].
Merck & Company, Whitehouse Station, NJ, received FDA approval to market Cancidas (caspofungin acetate) Intravenous Infusion for patients who are unresponsive to or cannot tolerate standard therapies for the invasive form of aspergillosis.
Merck currently has one anti-fungal drug on the market, Cancidas, but is one of the top makers of vaccines to prevent infectious diseases.
Comment: Cancidas inhibits the synthesis of an essential component of the fungal cell wall.
Merck & Company, Whitehouse Station, NJ, announced the Antiviral Advisory Committee of the US Food and Drug Administration (FDA) unanimously recommended approval of Cancidas (caspofungin acetate), the company's investigational intravenous antifungal medicine used for the treatment of invasive aspergillosis in patients who did not respond to or were intolerant of other antifungal therapies.
Schranz has worked on many anti-infective clinical and commercial development programs including CRIXIVAN, PRIMAXIN, CEFOXITIN, INVANZ, AUGMENTIN XR, ERAXIS, CANCIDAS, PREVENAR and PREVENAR 13.
Cancidas (caspofungin) is indicated for intravenous infusion in patients with aspergillus infection who are refractory to or intolerant of other treatments.
These events will likely impact prescribing trends and result in increased use of newer antifungals, such as Pfizer's Vfend and the echinocandins (such as Merck's Cancidas, Astellas's Mycamine and Pfizer's Eraxis) in order to target infections due to resistant Candida strains.